KYNTRA BIO, INC.
Close on Oct 19, 2026
- Market cap
- $21.37M
- P/E (TTM)
- 0.1
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | -$1.50M | $2.96 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 16, 2026 | After market close | $1.30M | $-3.51 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | After market close | $1.10M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | After market close | $1.30M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | After market close | $2.70M | $0.05 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 17, 2025 | After market close | $3.10M | $-0.08 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | $46.30M | $-0.17 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 6, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 26, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Nov 12, 2024, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| expected full year roxadustat net sales in China1 by FibroGen and the JDE | full year | $330.00M to $350.00M | New |
| net product revenue under U.S. GAAPGAAP | full year | $135.00M to $150.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Kyntra Bio filed with the SEC
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million
Other events · EX-99.1 to Form 8-K
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation
Other events · EX-99.1 to Form 8-K
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology
Regulation FD disclosure · EX-99.1 to Form 8-K
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · Listing notice · EX-99.1 to Form 8-K
FibroGen Announces the Sale of FibroGen China to AstraZeneca for
Material agreement · Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
FibroGen Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
FibroGen Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
FibroGen Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
Other events · EX-99.1 to Form 8-K
FibroGen Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Appoints Thane Wettig as Interim Chief Executive Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
Other events · EX-99.1 to Form 8-K
FibroGen Reports First Quarter 2023 Financial Results
Results of operations · EX-99 to Form 8-K
FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99 to Form 8-K
FibroGen Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
FibroGen Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
FibroGen Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
FibroGen Reports Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K